Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > KNSA Kiniksa Pharmaceuticals > Company Executives
KNSA Kiniksa Pharmaceuticals
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Sanj K. PatelChief Executive Officer and Chairman of the Board6.59M----52male04/28/2022
Mr. Michael R. MegnaChief Accounting Officer and Group Vice President, Finance------51male04/28/2022
Mr. Chris HeberligExecutive Vice President, Chief Financial Officer, Treasurer and Chief Accounting Officer------44male03/05/2020
Mr. John F. PaoliniSenior Vice President and Chief Medical Officer2.03M----57male04/28/2022
Mr. Mark RagosaSenior Vice President and Chief Financial Officer------48male04/28/2022
Mr. Ross MoatSenior Vice President and Chief Commercial Officer ------41male04/28/2022
Mr. Eben TessariSenior Vice President and Chief Operating Officer ------40male04/28/2022
Ms. Madelyn ZeylikmanVice President, Legal, Secretary and General Counsel--------female04/28/2022
Dr. Barry D. Quart,Pharm.D.Independent Director353.24K----65male04/28/2022
Mr. G. Bradley ColeIndependent Director346.94K----66male04/28/2022
Ms. Kimberly J. PopovitsIndependent Director344.24K----63female04/28/2022
Mr. Thomas R. MalleyIndependent Director361.94K----53male04/28/2022
Dr. Felix J. Baker,PhDLead Independent Director390.92K----53male04/28/2022
Dr. Stephen R. Biggar,M.D.,PhDIndependent Director351.82K----51male04/28/2022
Dr. Richard S. Levy,M.D.Independent Director347.69K----64male04/28/2022
Ms. Tracey McCainIndependent Director337.94K----54female04/28/2022
Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
SymbolLatest price%Chg